Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 11 April 2006
Vol. 2006, Issue 330, p. tw125
[DOI: 10.1126/stke.3302006tw125]

EDITORS' CHOICE

PHYSIOLOGY Therapy for Marfan Syndrome

Marfan syndrome (MFS) is a hereditary disorder characterized by systemwide defects in connective tissue. People with MFS have a greatly increased risk of developing an aortic aneurysm, a bulge in the wall of the aorta that can rupture and cause life-threatening internal bleeding. Studying a mouse model of MFS, Habashi et al. found that aneurysm formation is accompanied by activation of the transforming growth factor-β (TGF-β) signaling pathway in the aortic wall. Treatment of the MFS mice with losartan, a drug recently shown to antagonize TGF-β signaling in other disease states, almost completely normalized the aortic phenotype in the MFS mice, even after an aneurysm had formed. Losartan is already widely used to control high blood pressure, and the authors suggest that a prospective clinical trial in MFS patients is warranted.

J. P. Habashi, D. P. Judge, T. M. Holm, R. D. Cohn, B. L. Loeys, T. K. Cooper, L. Myers, E. C. Klein, G. Liu, C. Calvi, M. Podowski, E. R. Neptune, M. K. Halushka, D. Bedja, K. Gabrielson, D. B. Rifkin, L. Carta, F. Ramirez, D. L. Huso, H. C. Dietz, Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117-121 (2006). [Abstract] [Full Text]

Citation: Therapy for Marfan Syndrome. Sci. STKE 2006, tw125 (2006).



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882